News & Events Press Releases

January 29, 2014 - Vancouver’s Genesis Fertility Clinic is first in Canada to offer groundbreaking Early Embryo Viability Assessment (EEVA™) test

“Genesis Fertility Centre, an in vitro fertilization (IVF) clinic in Vancouver, today announces it is the first clinic in Canada, and the first commercial clinic in North America, to offer patients the Early Embryo Viability Assessment (Eeva) Test..." more >>

January 6, 2014 - New Clinical Data on Day 3 Embryo Transfers Using Eeva™ Technology Presented at the Association of Clinical Embryologists 2014 Conference

“Results of a clinical study utilizing the Eeva™ Technology by Auxogyn, that showed similar pregnancy rates among patients when embryos were transferred on Day 3 utilizing Eeva information versus Day 5 blastocyst transfers relying on morphology alone, were presented today...." more >>

November 1, 2013 - New ground-breaking IVF Technology now available in two Spanish clinics

“With an increasing number of UK couples travelling abroad for fertility treatment and Spain being amongst the most popular of the preferred destinations, both FIV Marbella and IVF Spain are proud to be the first infertility clinics to make a ground-breaking new approach to IVF commercially available in Spain...." more >>

October 31, 2013 - Renowned UK IVF clinic reflects on success with Eeva™: Enhanced patient experience a key benefit of new IVF technology

“Following the birth of the first Eeva baby conceived at the Glasgow Centre for Reproductive Medicine (GCRM), one of the UK’s most innovative IVF clinics and supporter of National Infertility Awareness Week, the clinic identifies the benefits of using the ‘Early Embryo Viablity Assessment’ (Eeva) test, a ground-breaking new approach to IVF that improves embryo selection..." more >>

July 25, 2013 - Auxogyn Announces Strategic Partnership with Valencia Infertility Institute

“Auxogyn, Inc., a company focused on revolutionizing the field of reproductive medicine by providing novel scientific and clinically validated solutions to IVF clinicians and their patients, today announced it has entered into a strategic partnership with the Valencia Infertility Institute (IVI), a global leader in reproductive medicine with 23 clinics throughout the world..." more >>

July 9, 2013 - Auxogyn Wins Prestigious Grant for Fertility Innovation

“Auxogyn, Inc., a privately held company that is revolutionizing the field of reproductive medicine by translating scientific discoveries in early embryo development into effective clinical tools, has been selected as the recipient of the prestigious Merck Serono Grant for Fertility Innovation (GFI) award..." more >>

July 2, 2013 - Auxogyn to Present New Data at the ESHRE 2013 Annual Meeting in London

“Auxogyn Inc., a company focused on revolutionizing the field of reproductive medicine by providing novel scientific and clinically validated solutions to IVF clinicians and their patients, today announced the presentation of the latest data on its Eeva™ Test at the 29th Annual Meeting of the European Society of Human Reproduction and Embryology (ESHRE) 2013..." more >>

June 14, 2013 - Baby Eva named after pioneering IVF test, First baby born in Scotland using new ground-breaking IVF technology

“Auxogyn announces the birth of the first baby in Scotland to be born using a ground-breaking new approach to IVF, the 'Early Embryo Viability Assessment' (Eeva™) test, that improves embryo selection..." more >>

June 5, 2013 - First baby born in the UK using Early Embryo Viability Assessment (Eeva™) test, Auxogyn at the forefront of revolutionizing IVF treatment

“Auxogyn, Inc. announced today the birth of one of the first babies to be born after embryologists used the Early Embryo Viability Assessment (Eeva™) Test to select and identify the most viable embryo for implantation into the mother’s womb..." more >>

May 22, 2013 - Auxogyn Selected to Present at European BioEquity Conference in Stockholm

“Auxogyn, Inc., a company focused on revolutionizing the field of reproductive medicine by providing novel scientific and clinically validated solutions to IVF clinicians and their patients, announced that Lissa Goldenstein, CEO and President of Auxogyn will be a featured speaker at the 14th European BioEquity Conference being held today in Stockholm, Sweden..." more >>

May 15, 2013 - Auxogyn Honored as a Finalist in the Red Herring 2013 Top 100 North America Award

“Auxogyn, Inc. announced today that it has been selected as a finalist for Red Herring's Top 100 North America award, a prestigious list honoring the year’s most promising private technology ventures from the North American business region..." more >>

May 7, 2013 - Auxogyn Announces Availability of Groundbreaking IVF Test, Eeva™, at Bourn Hall Clinic; Designed to Improve Outcomes

“The cutting-edge, new Early Embryo Viability Assessment™ (Eeva) Test designed to improve in vitro fertilization (IVF) outcomes is now available to couples seeking IVF treatment in East England. Using intelligent computer vision software to analyze key scientifically and clinically validated cell-division parameters, the Eeva Test is the first and only non-invasive IVF test..." more >>

February 28, 2013 - Auxogyn Appoints Women's Health Leader, Kathryn A. Tunstall, To Board of Directors

“Auxogyn, Inc., a company focused on revolutionizing the field of reproductive health, today announced the appointment of Kathryn A. Tunstall to the company's Board of Directors..." more >>

January 24, 2013 - Auxogyn Announces European Expansion of New Non-Invasive Early Embryo Viability Assessment (EEVA™) Test With Availability at First Clinic in Ireland

“Auxogyn Inc. today announced that Sims IVF is the first fertility clinic in Ireland to offer patients the Early Embryo Viability Assessment (Eeva) Test..." more >>

January 3, 2013 - Auxogyn Announces First European Patent for EEVA™ Test

“We are thrilled with the European Patent Office’s decision to issue this patent,” said Lissa Goldenstein, president and chief executive officer of Auxogyn. “This European patent provides further validation that bodies governing intellectual property worldwide recognize the inventive work done at Stanford University in the field of human embryology..." more >>

December 27, 2012 – Fertility Road: Embryo Monitoring Designed to Improve IVF Outcomes 

"Revolutionary new non-invasive test that uses intelligent imaging software to measure and predict with more accuracy which embryos will likely grow to the blastocyst stage..." more>>

December 4, 2012 – Auxogyn Announces Publication of New Data Key to Identifying Which Developing Human Embryos are Most Likely to Result in Successful IVF Pregnancy

Auxogyn, Inc., a company focused on revolutionizing the field of reproductive health, today announced new data key to identifying which developing human embryos are the most likely to result in successful pregnancies during in vitro fertilization (IVF) procedures. more»

December 4, 2012 – Auxogyn Announces IVF Research Using its EEVA Test Awarded Top Honor at Fertility Society of Australia Scientific Meeting

Auxogyn, Inc., a company focused on revolutionizing the field of reproductive health, today announced that research involving the use of the company’s flagship product, the Early Embryo Viability Assessment (Eeva) Test, was recognized by the Fertility Society of Australia at its 2012 Scientific Meeting with the Ferring “Best Scientific Paper Award.” more»

October 22, 2012 – Auxogyn Presents New Data Validating Eeva's Ability to Predict Blastocyst Development in IVF By Day 3 With High Specificity and Consistency

Auxogyn, Inc., a company focused on revolutionizing the field of reproductive health, today announced two presentations describing new data from a prospective, cohort study conducted at multiple independent centers. more»

October 18, 2012 – Merck Serono and Auxogyn Announce Collaboration on EEVA™ Test

Merck Serono, a division of Merck, Darmstadt, Germany, and Auxogyn, Inc., a company focused on revolutionizing the field of reproductive health, today announced that they have entered into a strategic agreement focused on Auxogyn’s proprietary Early Embryo Viability Assessment (Eeva) Test. more»

October 11, 2012 – Auxogyn Strengthens Intellectual Property Rights for EEVA™ Test

Auxogyn, Inc., a company focused on revolutionizing the field of reproductive health, today announced that the U.S. District Court for the Northern District of California has ruled in favor of Auxogyn and Stanford University and dismissed a patent lawsuit initiated by Unisense Fertilitech. more»

September 17, 2012 – Auxogyn and Hewitt Fertility Center Announce First Availability of New Non-Invasive Early Embryo Viability Assessment (EEVA) Test in the European Union

Auxogyn, Inc., a company focused on revolutionizing the field of reproductive health, today announced the launch of its Early Embryo Viability Assessment (Eeva) Test in the European Union (EU), with the first installation at the Hewitt Fertility Centre in Liverpool. more»

July 23, 2012 – Auxogyn Receives CE Mark for Non-Invasive Early Embryo Viability Assessment (EEVA) Test

Auxogyn, Inc., a company focused on revolutionizing the field of reproductive health, today announced that it has received CE mark approval to market its flagship product, the Early Embryo Viability Assessment (Eeva) Test, which is designed to improve in vitro fertilization (IVF) outcomes by providing clinicians and patients with objective information that will enable them to predict embryo viability with a new level of accuracy. more»

July 2, 2012 – Auxogyn Presents New Data Showing the Ability of EEVA™ to Non-Invasively Predict Embryo Advancement With Increased Accuracy

Auxogyn, Inc., a company focused on revolutionizing the field of reproductive health, today presented data showing the ability of its flagship product, the Early Embryo Viability Assessment (Eeva) Test, to predict embryo advancement with a new level of accuracy. The Eeva™ Test uses intelligent computer vision software to measure key parameters from video images and predicts with high accuracy at the cleavage stage which embryos will likely grow to the blastocyst stage. more»

June 19, 2012 – Auxogyn and Reproductive Medicine Associates of New Jersey Partner to Advance In Vitro Fertilization Research

Auxogyn, Inc., a company at the forefront of reproductive health innovation, today announced the commencement of a groundbreaking research study with Reproductive Medicine Associates of New Jersey (RMANJ), an internationally-renowned fertility clinic that has pioneered and successfully implemented cutting-edge clinical advancements to more accurately detect healthy embryos for patients undergoing in vitro fertilization (IVF). more»

June 5, 2012 – Auxogyn Raises $18 Million in Series B Funding

Auxogyn, Inc., a privately-held company advancing women’s reproductive health, today announced it raised $18 million through a Series B financing. The proceeds will be used to support regulatory clearance and commercial launch of Auxogyn's Early Embryo Viability Assessment, Eeva, a non-invasive test designed to provide objective information regarding the viability of embryos during in vitro fertilization (IVF) procedures. more»

February 9, 2012 – Auxogyn Takes Top Honor As “Most Promising Company” at Personalized Medicine World Conference 2012

Auxogyn, Inc., a privately-held company advancing women’s reproductive health, announced today that the Personalized Medicine World Conference (PMWC) and Prescience International selected the Auxogyn as the ‘Most Promising Company’ at PMWC2012 annual conference, held January 23-24, 2012. more»

February 2, 2012 – Auxogyn Announces the Close of the Final Tranche of its Series A Financing, Bringing the Total Funding to $20 Million.

Auxogyn, Inc., a privately-held company focused on advancing women’s reproductive health, today announced the close of the final tranche of its Series A financing, bringing the total funding to $20 million. The initial tranche was placed in May 2010, and investors in the round include Kleiner Perkins Caufield and Byers, TPG Biotech and Merck Serono Ventures. more»

June 27, 2011 - Auxogyn Announces Issuance of Key Patent Covering Predictive Embryo Assessment Parameters for In Vitro Fertilization

Auxogyn, Inc., a privately held medical technology company focused on women’s reproductive health, today announced that the U.S. Patent and Trademark Office (USPTO) issued patent number 7,963,906 covering three predictive parameters for the assessment of embryo viability during in vitro fertilization (IVF) procedures used in Auxogyn’s early embryo viability assessment (Eeva™) System.... more»

July 4, 2011 – Auxogyn Announces Initiation of Clinical Study for Non-Invasive Embryo Assessment Technology Used During In Vitro Fertilization

Auxogyn, Inc., a privately held medical technology company focused on women’s reproductive health, today announced that it initiated a multi-center clinical study to validate its early embryo viability assessment (Eeva™) System for use in in vitro fertilization (IVF). more»

October 4, 2010 - Auxogyn Licenses Non-Invasive Embryo Assessment Technology from Stanford University

Auxogyn, Inc., a privately held medical technology company focused on women’s reproductive health, today announced that it acquired an exclusive license from Stanford University to develop a set of products that may allow medical practitioners in the field of assisted reproduction to significantly improve the effectiveness of in vitro fertilization (IVF) procedures... more»